An underground market for unlicensed slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.
Experimental Treatment Acquiring Traction Via Social Media
The experimental drug, which is still in clinical trials, is being promoted by online personalities for its alleged weight-reducing effects. Followers are encouraged to message these accounts directly for supplier links, while also receiving discount codes.
Thriving Commerce on Messaging Platforms
Additionally, a flourishing market exists on messaging services, where communities with thousands of participants share “before and after” photos, administration instructions and assertions of next-day UK delivery. Vendors market the substance there before directing customers to WhatsApp for purchases.
Learning About The Experimental Drug
Retatrutide is an experimental injectable created by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist patients lose up to a quarter of their body weight. Referred to as the “triple G”, the drug is being promoted online as the successor to Ozempic.
Medical Experts Express Worries
However, physicians and pharmacists have cautions that the distribution of what is still an unapproved medication in the United Kingdom is worrisome and could result in individuals injecting products of uncertain source.
Several professionals stated the demand for the experimental drug could be linked to the rising price of approved weight loss products such as Mounjaro.
Legal Position and Enforcement
Selling the unapproved drug on TikTok or messaging apps is prohibited in the UK, as it is an unlicensed drug that cannot be marketed or supplied for personal consumption under the British medical regulations.
Some influencers attempt to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still breach medicines, advertising, and customer laws, risking fines, prosecution or prison.
Service Response and Content Removal
Based on the social media company, the service has taken down violative material and prohibited related keywords and query recommendations. The company said it was committed to keeping the platform safe and allocating resources in enhancing enforcement strategies.
Digital Trading Operations
Research also found communities with up to nine thousand members marketing retatrutide using the platform's built-in search feature, which operates like a online catalog. Entering “retatrutide” immediately displays groups with thousands of users, filled with images of weight loss, glowing testimonials and detailed instructions for preparing or injecting at residence.
After minutes of entering one community, a seller shared contact information, where most transactions occur. The seller provided an instruction manual and guaranteed shipping within 48 hours. When questioned whether the product was genuine, one seller responded: “You can’t be sure.” Another shared a photo of a alleged testing documentation. None asked about body mass, medical conditions or past usage.
Item Details and Costs
Within these communities, messages show black plastic parcels with postal service labels, claiming to contain new batches. One message read: “It took eight of us to load them this morning.”
Customers can select between dry substance containers, prepared at residence with sterile water, or ready-to-use pens typically priced at £160 for 20mg. When asked how long a injector should last, vendors give contradictory responses ranging from a several days to “depends on your body”.
Service Oversight and Safety Actions
A representative for Telegram stated it regularly moderated harmful material on its platform including material that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“Individuals are injecting materials they can’t verify. Although the research behind this drug is valid, these digital versions may not include what they advertise,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the increase in interest to current price rises for authorized slimming drugs such as Mounjaro. “With costs increasing, patients are using social media. But counterfeit injections are highly risky. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she explained.
Her team has already seen individuals harmed by self-injection from unconfirmed suppliers. “We recognize the disappointment, but purchasing from Telegram or WhatsApp is gambling with your well-being,” said Wyllie. “These substances could be contaminated or incorrectly dosed.”
Manufacturer Statement
A spokesperson from Eli Lilly said the substance was in third stage clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for personal consumption,” they said, adding that any product “misleadingly claiming itself as a company experimental substance not yet authorized … may expose users to possibly significant health risks”.
